192 related articles for article (PubMed ID: 25747742)
21. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
22. Characterization of developmental pathway of natural killer cells from embryonic stem cells in vitro.
Tabatabaei-Zavareh N; Vlasova A; Greenwood CP; Takei F
PLoS One; 2007 Feb; 2(2):e232. PubMed ID: 17311098
[TBL] [Abstract][Full Text] [Related]
23. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.
Perussia B; Ramoni C; Anegon I; Cuturi MC; Faust J; Trinchieri G
Nat Immun Cell Growth Regul; 1987; 6(4):171-88. PubMed ID: 2960890
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
25. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V
Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.
Kim EK; Ahn YO; Kim S; Kim TM; Keam B; Heo DS
Cytotherapy; 2013 Feb; 15(2):231-241.e1. PubMed ID: 23321334
[TBL] [Abstract][Full Text] [Related]
27. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
28. Understanding of molecular mechanisms in natural killer cell therapy.
Yoon SR; Kim TD; Choi I
Exp Mol Med; 2015 Feb; 47(2):e141. PubMed ID: 25676064
[TBL] [Abstract][Full Text] [Related]
29. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
30. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
31. Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.
Matsubara H; Niwa A; Nakahata T; Saito MK
Biochem Biophys Res Commun; 2019 Jul; 515(1):1-8. PubMed ID: 30948156
[TBL] [Abstract][Full Text] [Related]
32. [Expansion of human natural killer cells ex vivo].
Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
[TBL] [Abstract][Full Text] [Related]
33. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic origin of human natural killer (NK) cells: generation from immature progenitors.
Silva MR; Kessler S; Ascensao JL
Pathobiology; 1993; 61(5-6):247-55. PubMed ID: 7507682
[TBL] [Abstract][Full Text] [Related]
35. Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes.
Clausen J; Enk M; Vergeiner B; Eisendle K; Petzer AL; Gastl G; Gunsilius E
Biol Blood Marrow Transplant; 2004 Oct; 10(10):691-7. PubMed ID: 15389435
[TBL] [Abstract][Full Text] [Related]
36. Production of cytotoxic, KIR-negative NK cells from CD34+ cord blood cells with the use of Notch signaling.
Beck RC
Transfusion; 2011 Nov; 51 Suppl 4():145S-152S. PubMed ID: 22074625
[TBL] [Abstract][Full Text] [Related]
37. Large-scale generation of natural killer lymphocytes for clinical application.
Luhm J; Brand JM; Koritke P; Höppner M; Kirchner H; Frohn C
J Hematother Stem Cell Res; 2002 Aug; 11(4):651-7. PubMed ID: 12201953
[TBL] [Abstract][Full Text] [Related]
38. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
[TBL] [Abstract][Full Text] [Related]
39. [Effects of FPIL6/IL2 on the differentiation and proliferation of lymphoid in the ML-IC assay].
Fan EJ; Song JM; Xu SR; Zhao CH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):30-5. PubMed ID: 12905836
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo expansion of CD3
Hosseini E; Ghasemzadeh M; Kamalizad M; Schwarer AP
Stem Cell Res; 2017 Mar; 19():148-155. PubMed ID: 28171825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
